You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Myriad Genetics' BRACAnalysis Diagnostic System will be reimbursed in Japan as a test to identify whether individuals with hereditary breast and ovarian cancer syndrome have BRCA1/2 mutations.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.
The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.